BIOMAT Database Logo BIOMAT Database Logo

Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. 1995

I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
Regional Paediatric Cystic Fibrosis Unit, St James's University Hospital, Leeds.

OBJECTIVE To assess the benefit of nebulised amiloride added to the standard inpatient treatment of a respiratory exacerbation in cystic fibrosis. METHODS Prospective, randomised, double blind, placebo controlled trial. METHODS 27 cystic fibrosis patients (mean age 12.8 years). METHODS Two hospitals in Leeds, UK. RESULTS Both forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) showed improvements over the course of treatment, although there was no difference in respiratory function between the two groups at any of three time periods during the study. The time to reach peak FVC was significantly reduced in the amiloride group (4.2 v 7.6 days; 95% CI 0.4 to 6.4 days), but not in the time to reach peak FEV1 (5.7 v 7.9 days; 95% CI -1.2 to 5.6 days). CONCLUSIONS Amiloride did not result in a greater overall improvement in respiratory function. There was a suggestion that it may have an effect on the rate of improvement, and thus may possibly influence the duration of treatment. This hypothesis deserves further evaluation.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005100 Expectorants Agents that increase mucous excretion. Mucolytic agents, that is drugs that liquefy mucous secretions, are also included here. Expectorant,Mucolytic,Mucolytic Agent,Mucolytic Agents,Mucolytics,Agent, Mucolytic,Agents, Mucolytic
D005260 Female Females
D005541 Forced Expiratory Volume Measure of the maximum amount of air that can be expelled in a given number of seconds during a FORCED VITAL CAPACITY determination . It is usually given as FEV followed by a subscript indicating the number of seconds over which the measurement is made, although it is sometimes given as a percentage of forced vital capacity. Forced Vital Capacity, Timed,Timed Vital Capacity,Vital Capacity, Timed,FEVt,Capacities, Timed Vital,Capacity, Timed Vital,Expiratory Volume, Forced,Expiratory Volumes, Forced,Forced Expiratory Volumes,Timed Vital Capacities,Vital Capacities, Timed,Volume, Forced Expiratory,Volumes, Forced Expiratory
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
September 2002, The European respiratory journal,
I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
Pulmonary deposition of nebulised amiloride in cystic fibrosis: comparison of two nebulisers.
October 1991, Thorax,
I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial.
August 2012, Lancet (London, England),
I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis.
February 2000, Archives of disease in childhood,
I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial.
May 2019, Archives of disease in childhood. Fetal and neonatal edition,
I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
A double-blind controlled trial of anti-Pseudomonas chemotherapy of acute respiratory exacerbations in patients with cystic fibrosis.
August 1981, The Journal of pediatrics,
I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
A simple metric for cystic fibrosis respiratory exacerbations.
March 2017, The Journal of pediatrics,
I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
Correction: Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial.
March 2020, Archives of disease in childhood. Fetal and neonatal edition,
I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
Role of Tris-CaEDTA as an adjuvant with nebulised tobramycin in cystic fibrosis patients with Pseudomonas aeruginosa lung infections: A randomised controlled trial.
March 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
I M Bowler, and B Kelman, and D Worthington, and J M Littlewood, and A Watson, and S P Conway, and S W Smye, and S L James, and T A Sheldon
Self-management intervention to reduce pulmonary exacerbations by supporting treatment adherence in adults with cystic fibrosis: a randomised controlled trial.
May 2022, Thorax,
Copied contents to your clipboard!